Every story in this issue with a short summary, so you can decide what to read before leaving the site. Summaries are written by AI (Claude) only from each publisher's own description and checked by Jev for anything not in that description. They are not full translations. Follow "Read the original" for the full story.
Doximity (NYSE:DOCS) has rolled out DoseCheck, an AI-driven medication dosing verification feature embedded in its Doximity Ask tool. DoseCheck adds a deterministic, rule-based layer that cross-checks AI dosing suggestions to help reduce medication dosing errors. The company is integrating UpToDate.
Read the original →The AI in sepsis warning systems market was valued at $213.8M in 2025. It is projected to grow from $251.9M in 2026 to $1,176.4M by 2033, at a CAGR of 24.6%.
Read the original →An expert consensus governing artificial intelligence applications in laboratory medicine was officially released in Shanghai on October 21.
Read the original →A Stony Brook University study published online in Digital Medicine says AI could help physicians prepare hospital patient discharge summaries more efficiently.
Read the original →As health systems work towards an AI-enabled future, BJC HealthCare's Philip Payne suggests consulting the past.
Read the original →Vendan Ananda Kumararajah examines four hypothetical AI crises affecting Britain's banking, NHS, border controls and food distribution. He highlights the safeguards needed to prevent systemic disruption.
Read the original →A hospital worker at a Somerset NHS trust recently accessed up to 200 patient records without permission and shared a screenshot of one patient.
Read the original →ScionxBio licenses its xRNA TERA platform to Sanofi. The platform targets chronic protein-deficiency diseases with AI-engineered mRNA that lasts weeks, not days.
Read the original →H1 loss narrowed to €336k, with €194k in net investment gains including a €188k one-time payment. The strategy pivoted to AI and BioTech, while a €2.4m share placement supports liquidity and a proposed Zirnostics investment.
Read the original →Thailand wants to become a regional AI medical hub by developing AI models tailored to Southeast Asian populations. It aims to turn decades of clinical research into advances in precision medicine, drug discovery and cancer treatment.
Read the original →Korea is hosting a conference on AI and natural product drug discovery. Global experts have gathered in Gangneung to spotlight AI's role in faster, cheaper natural product therapies.
Read the original →MIT professors Regina Barzilay and Jim Collins were recognized with the Pritzker Prize for AI and Science Research Excellence. The award recognizes their work in AI-enabled antibiotic discovery.
Read the original →Quantitative CT from two platforms, Brainomix's e-Lung and a UCLA algorithm, both detected nintedanib's effect in the Phase III INBUILD substudy. Brainomix's Peter George said e-Lung's reticulovascular score alone predicted later mortality, but FVC remains the regulator's primary endpoint.
Read the original →There have been calls for medical artificial intelligence to move beyond detecting diseases and assisting with diagnosis. The aim is to expand into "Care AI".
Read the original →A study of AI in primary care involved 98 patients and logged 0 safety stops. The description says it covers how the trial worked, what clinicians found, and what it means for practices in 2026.
Read the original →AI note-takers make meeting records cheap, but the meeting itself costs as much as before. Workplace trials find time saved on documentation, with little sign of higher output. Whether managers end up with less work depends on how the group sets its meeting load.
Read the original →Google announced on October 29 that it will open a research hub in Singapore to support the adoption of artificial intelligence by medical institutions there.
Read the original →The Pharmaceuticals and Medical Devices Agency (PMDA) issued an administrative notice dated the 2nd setting out its basic approach to using AI in pharmaceutical affairs. The aim is to use AI soundly in regulatory judgments and decision-making, covering areas from the development of drugs and medical devices onward.
Read the original →Medical AI developer MENTRA (Minato-ku, Tokyo) announced on October 31 that its psychiatry and psychosomatic medicine AI service MENTRA now offers a web questionnaire before first visits and call routing. Assignment of psychiatric social workers is also automated, aiming to reduce the workload of first-visit reception.
Read the original →